Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension by Beckers, Henny JM et al.
© 2009 Beckers et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Ophthalmology 2009:3 593–599
Clinical Ophthalmology
593
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Role of fixed-combination brinzolamide  
1%/timolol 0.5% in the treatment of elevated 
intraocular pressure in open-angle glaucoma  
and ocular hypertension
Henny JM Beckers 
Jan SAG Schouten 
Carroll AB webers
University eye Clinic, Maastricht,  
The Netherlands
Correspondence: Henny JM Beckers  
University eye Clinic, Maastricht,  
The Netherlands 
Tel +31 43 387 53 42 
Fax +31 43 387 53 43 
email henny.beckers@mumc.nl
Abstract: Brinzolamide 1%/timolol 0.5% is a new fixed-combination for the treatment of 
open-angle glaucoma or ocular hypertension. Brinzolamide/timolol has a favorable safety 
profile, with an incidence of ocular burning and stinging 5%. Published data show that 
brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% have similar efficacies for 
lowering intraocular pressure (IOP). There is some evidence that brinzolamide/timolol may 
be more comfortable. Although patients receiving brinzolamide/timolol may experience more 
blurred vision on instillation, some data show a preference for brinzolamide/timolol over 
dorzolamide/timolol. Although available data to assess the role of brinzolamide/timolol in daily 
clinical practice are still limited, these first results suggest the agent to be a reasonable alternative 
for patients who do not reach target IOP with monotherapy.
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Introduction
Reduction of elevated intraocular pressure (IOP) is the only proven approach to 
protect against visual field loss in patients with open-angle glaucoma (OAG) or ocular 
hypertension (OHT), making ocular hypotensive agents critical to the management of 
these patients. First-line therapy for elevated IOP is typically a single topical agent from 
one of the following classes of drugs: alpha-2 adrenergic receptor agonists, beta-blockers, 
topical carbonic anhydrase inhibitors (CAIs), and prostaglandin derivatives/prostamides.1 
If single-agent therapy is effective but not sufficient to reach a patient’s target IOP, a second 
hypotensive drug is added. Evidence shows that this strategy can produce an additional 
IOP decrease.2 The 2-drug combination can be comprised of 2 individual agents or 
a fixed-combination product. A recent meta-analysis confirmed that these 2 types of 
glaucoma therapies produce equivalent efficacy.3 In a large study (N = 3333) of patients 
taking glaucoma medications, the majority (79%) reported that they were satisfied with 
their eye drops; however, nearly 1 in 10 patients (9%) were likely to have their medication 
changed at their next visit due to side effects.4 Each hypotensive agent has a characteristic 
side effect profile, but fixed-combination products as a group have a number of advantages 
over the instillation of 2 individual drugs.5 First, a fixed-combination product requires 
dispensing from only 1 bottle, making it more convenient than dispensing 2 separate 
doses. The European Glaucoma Society recommended that fixed-combination products be 
used, whenever available, in place of 2 separate instillations.1 Fixed-combination products Clinical Ophthalmology 2009:3 594
Beckers et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
also avoid washout, which occurs when inadequate time is 
allowed between instillation of the first and second drugs.6 
Moreover, the lifetime exposure to preservatives is reduced 
with fixed-combination products. Because preservatives 
have been shown to be associated with both in vitro ocular 
toxicities (eg, cellular apoptosis, conjunctival inflammation),7,8 
and clinical signs and symptoms of ocular irritation (eg, dry 
eye, burning/stinging, discomfort),9,10 reducing exposure 
to preservatives should facilitate the maintenance of ocular 
surface health in these patients requiring chronic topical 
therapies. Finally, costs and impact on quality of life can 
lead to non-compliance in patients who have to use multiple 
medications. Some of these disadvantages can also be reduced 
by using fixed combinations.11
The fixed-combination dorzolamide 2%/timolol 0.5% 
(Cosopt®; Merck & Co., Inc., Whitehouse Station, NJ, 
USA) has been shown to be at least as effective as separate 
instillations of the component drugs.12 Side effects that 
have been described are ocular stinging and burning 
upon instillation and a bitter taste.13 The safety profiles 
of the individual components show that the incidence of 
stinging and burning of the fixed-combination product is 
most similar to dorzolamide (Trusopt®; Merck & Co., Inc., 
Whitehouse Station, NJ, USA) alone.14 Recently, the fixed 
combination dorzolamide/timolol has also become available 
in several countries in a preservative-free variant. Recently, 
a new fixed-combination product, brinzolamide 1%/timolol 
0.5% (Azarga®; Alcon Laboratories, Inc., Fort Worth, TX, 
USA), has been introduced. The aim of this review article 
is to explore the molecular and clinical characteristics of 
brinzolamide/timolol to determine its potential role in the 
management of patients with OAG or OHT.
Brinzolamide 1%/timolol 0.5%
The brinzolamide/timolol fixed combination is comprised 
of the CAI brinzolamide and the beta-blocker timolol 
and is recommended to be dosed twice daily (bid).15 It is 
delivered as a suspension with a pH of 7.2 and is preserved 
with benzalkonium chloride 0.01%.15 The concentration of 
brinzolamide is 1% (10 mg/mL), equal to that of brinzolamide 
ophthalmic suspension (Azopt®; Alcon Laboratories, Inc., 
Fort Worth, TX, USA)16 and the timolol concentration is 0.5% 
(5 mg/mL), equal to that of single-agent timolol.17–19
Mechanisms of action  
and pharmacokinetics
Brinzolamide is a highly specific, reversible inhibitor of 
carbonic anhydrase, an enzyme which is present in the lens, 
cornea, ciliary body and retina.20,21 Blocking this enzyme is 
believed to reduce aqueous humor formation by slowing the 
formation of bicarbonate ions with subsequent reduction 
in sodium and fluid transport.16 Brinzolamide-induced 
inhibition of CA II, a key carbonic anhydrase isoenzyme, 
occurs both during the day and at night, apparently not 
subjected to the circadian rhythm.22,23 A single drop of 
brinzolamide can lower IOP for approximately 12 hours, 
and its washout time after chronic instillation is 7 days.22
Contraindications of topical carbonic anhydrase 
inhibitors are renal failure and sulfonamide allergy. Caution 
should be taken in patients with a compromised corneal 
endothelium.
Beta-adrenergic antagonists (beta blockers) reduce IOP 
through blocking of the B1-adrenoreceptor (non-selective 
and selective beta blockers) and B2-adrenoreceptors 
(non-selective beta blockers) of the ciliary body epithelium 
which leads to a reduced inflow of aqueous humor in the 
anterior chamber of the eye. Most beta blockers are dosed 
bid, although the gel-forming solutions are often equally 
efficacious in a once daily regime.24–26 The activity of timolol 
is subject to circadian changes, showing less efficacy at 
night.27 Contraindications for the use of timolol are asthma, 
obstructive pulmonary disease, sinus bradycardia and 
heart block.
Effect on ocular blood flow
Some aspects of ocular blood flow may be reduced in certain 
patients with glaucoma.28 Reduced ocular perfusion pressure 
probably is an independent risk factor for the development 
of OAG.29–34
Numerous studies have shown that timolol does not 
affect ocular blood flow;35–37 however, several studies have 
reported a possible increased resistance to blood flow.38,39 
Although there is no conclusive evidence, many studies 
have suggested that the topical carbonic anhydrase inhibitor 
dorzolamide probably has a positive effect on ocular blood 
flow. In addition, a positive effect on ocular blood flow for 
the fixed combination of dorzolamide/timolol has been 
shown.40–46 The effect of brinzolamide on ocular blood flow 
is less well established, mainly due to a limited number of 
publications on the subject. Several studies have shown that 
brinzolamide positively affects ocular blood flow,47–49 but 
others have shown no effect.50,51 Until now, the effects of 
brinzolamide/timolol on ocular blood flow have been unclear. 
Studies on the effects of the combination brinzolamide/
timolol (concomitant or fixed combination) on ocular blood 
flow are scarce.Clinical Ophthalmology 2009:3 595
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IOP-lowering efficacy
We performed a systematic review of the IOP-lowering 
efficacy of the combination of brinzolamide and timolol. 
Articles were identified through a computerized search 
in Medline, Embase, and the Cochrane Controlled Trials 
Register. For details on search strategy, selection process 
and data extraction we refer to the papers of van der Valk 
et al52 and Webers et al2,53 Potentially eligible for inclusion in 
this systematic review were randomized clinical trials on the 
combination of timolol and brinzolamide written in English, 
French, German or Dutch and published between January 
1995 and July 2009.
The initial search revealed 1169 papers. Based on the 
title, abstract and medical subject heading (MeSH) words, 
1128 papers were excluded. The most important reasons 
for excluding articles were that the primary endpoint in the 
studies was not IOP but, for instance, side-effects, visual field 
outcome or impact on ocular blood flow, that articles reported 
on glaucoma topics other than IOP lowering of drugs, or that 
studies reported on IOP lowering of monotherapies. From 
the remaining 41 papers that were printed or photocopied 
36 papers had to be excluded. The major reasons were a 
non-randomize design (n = 9), a combination of other drugs 
(n = 7) or a different outcome parameter (n = 9).
The results of the included studies54–58 are shown in 
Table 1.
An earlier systematic review showed no significant 
differences between concomitant and fixed use of the 
combination of 0.5% timolol bid and 2% dorzolamide bid.2 
The mean additional IOP decrease of 2% dorzolamide bid 
or tid when added to 0.5% timolol bid was 15.7% at trough 
and 20.1% at peak.53 The present study gives similar results 
for the IOP decrease of the concomitant use of 0.5% timolol 
bid and 1% brinzolamide bid or tid, varying between 13.2% 
at trough and 20.3% at peak. The 2 papers reporting on 
the fixed combination brinzolamide/timolol57,58 revealed 
similar IOP-lowering results. These studies both used a 
washout design. Moreover, the Manni study58 also reported 
similar IOP-lowering results for the brinzolamide/timolol 
combination when directly compared with the fixed 
combination dorzolamide/timolol.
Safety and tolerability
In the study by Kaback57 et al a higher incidence of blurred 
vision was found in the group of patients treated with 
brinzolamide/timolol versus patients treated with timolol 
0.5% alone; however, reported dysgeusia was markedly lower 
with the fixed combination. The Manni study showed similar 
safety profiles for brinzolamide/timolol and dorzolamide/
timolol, with the exceptions of a lower incidence of any 
adverse events and fewer patients with ocular burning 
and stinging. In the brinzolamide/timolol group, a higher 
incidence of blurred vision was reported.58
A study by Vold and colleagues59 directly examined the 
ocular discomfort associated with the use of brinzolamide/
timolol or dorzolamide/timolol after 1 week of dosing. 
Mean ocular discomfort scores (judged from a scale of 
0 [none] to 4 [very severe]) were significantly lower in 
patients receiving brinzolamide/timolol than in those receiv-
ing dorzolamide/timolol. Although this study had a very 
short follow-up period, the results confirm the results from 
the Manni study.
Because  the  beta-blocker  component  of  the  2 
CAI-containing fixed-combination products is identical, 
any dissimilarities in tolerability are likely due to differences 
in pH between brinzolamide and dorzolamide. Dorzolamide/
timolol is formulated at an acidic pH of 5.65,13 whereas 
brinzolamide/timolol has a near physiologic pH of 7.2.15 This 
hypothesis is supported by results from 2 multicenter studies 
published in 2000 which used study designs similar to the Vold 
comfort study, comparing the ocular comfort of the single 
agents brinzolamide and dorzolamide.60 Significantly more 
patients in both studies reported no ocular discomfort with 
brinzolamide than with dorzolamide. In an ocular discomfort 
study in which patients taking latanoprost, dorzolamide, and 
timolol combination therapy were randomized to switch the 
CAI component to brinzolamide or to continue dorzolamide, 
patients in the brinzolamide group, but not the control 
group, experienced a significant decrease in ocular irritation, 
although these patients had a numerical increase in blurred 
vision.61 Another study from Michaud and colleagues, which 
compared brinzolamide and dorzolamide each given twice 
daily in addition to timolol 0.5%, also found significantly less 
ocular burning and stinging in the brinzolamide group.55
The results from the studies mentioned above suggest that 
brinzolamide/timolol may be more tolerable than (preserved) 
dorzolamide/timolol, at the cost of an increase in blurred 
vision. The authors are not aware of any studies comparing 
the ocular comfort of unpreserved dorzolamide/timolol to 
preserved dorzolamide/timolol or other topical medication.
Patient preference
All of the clinical characteristics described above – efficacy, 
safety, and tolerability – probably affect patient preference. 
Patient preference, in turn, may improve adherence. 
Barnebey et al suggested that better patient adherence after Clinical Ophthalmology 2009:3 596
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Table l Run-in medication, treatment combination after adding brinzolamide, baseline characteristics, time point(s) of intraocular pressure 
measurements and absolute (mmHg) and relative (%) decrease from baseline intraocular pressure for peak and trough time points
  




No. of patients 
baseline (% with-
drawals)
Sex (M/F) Mean age (y) POAG (%) OHT (%) Endpoint of  
measurement  
(months)
Baseline IOP  
(mmHg)  
mean ± SD






(%) mean ± SD
Trough
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +0 timolol 
+0 brinzolamide
–3.3 ± nr –13.2 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +0 timolol  
+0 brinzolamide
–3.6 ± 3.0 –14.1 ± 11.4
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 27.1 ± 2.7 +0 timolol  
+0 brinzolamide
–8.3 ± 3.8 –30.6 ± 13.6
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 27.3 ± nr +0 timolol  
+0 brinzolamide
–9.1 ± nr –33.3 ± nr
Peak
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +2 timolol  
+2 brinzolamide
–3.3 ± nr –14.3 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +2 timolol  
+2 brinzolamide
–4.9 ± 2.6 –20.3 ± 10.5
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 25.8 ± 3.0 +2 timolol  
+2 brinzolamide
–8.7 ± 3.9 –33.7 ± 14.7
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 25.9 ± nr +2 timolol  
+2 brinzolamide
–9.1 ± nr –34.9 ± nr
Abbreviations: M, male; F, female;   Y, year; POAG, primary open-angle glaucoma; OHT, ocular hypertension; IOP, intraocular pressure; SD, standard deviation; bid, twice daily; 
tid, thrice daily; nr, not reported.
a transition from dorzolamide to brinzolamide correlated 
with a patient preference for brinzolamide.62 In a crossover 
study, Mundorf and colleagues found better comfort scores 
for brinzolamide/timolol than for dorzolamide/timolol.63 
Although the follow up in this study was very limited, 
a majoritiy of patients preferred brinzolamide/timolol. 
Ocular burning and stinging are very frequent side effects 
of topical glaucoma medications.4 In a willingness-to-pay 
analysis of topical ocular medications, it was found that 
nearly 75% of patients would be willing to pay a premium 
for a medication that would eliminate stinging and burning 
upon instillation.64
Summary
Published data show that brinzolamide 1%/timolol 0.5% 
and dorzolamide 2%/timolol 0.5% have similar efficacies 
for lowering IOP. The main difference between these agents 
appears to be in the safety profiles, with dorzolamide/
timolol producing more ocular burning and stinging, 
probably due to differences in pH. In several studies, 
brinzolamide/timolol was rated as the more comfortable 
medication for new users. Although patients receiving 
brinzolamide/timolol may experience more blurred vision 
upon instillation, some data suggest a preference for 
brinzolamide/timolol over dorzolamide/timolol in new users. 
However, the follow up of these studies was short or very 
short. Patients who have used their medication for a longer 
period may probably be more satisfied with their medication. 
The effect of excluding preservatives in dorzolamide/timolol 
on comfort and/or patient preference has not been studied.
Thus, although available data to assess the role of 
brinzolamide/timolol are still limited, its apparently similar 
efficacy and probably improved tolerability relative to 
dorzolamide/timolol make it a reasonable alternative for 
patients who do not reach target IOP with monotherapy. 
Further evaluation of the fixed combination brinzolamide/
timolol in daily clinical practice will elucidate how this 
novel combination agent will be accepted by physicians and 
ultimately incorporated into the management of patients 
with elevated IOP.Clinical Ophthalmology 2009:3 597
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measurements and absolute (mmHg) and relative (%) decrease from baseline intraocular pressure for peak and trough time points
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Sex (M/F) Mean age (y) POAG (%) OHT (%) Endpoint of  
measurement  
(months)
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mean ± SD






(%) mean ± SD
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Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +0 timolol 
+0 brinzolamide
–3.3 ± nr –13.2 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +0 timolol  
+0 brinzolamide
–3.6 ± 3.0 –14.1 ± 11.4
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 27.1 ± 2.7 +0 timolol  
+0 brinzolamide
–8.3 ± 3.8 –30.6 ± 13.6
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 27.3 ± nr +0 timolol  
+0 brinzolamide
–9.1 ± nr –33.3 ± nr
Peak
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +2 timolol  
+2 brinzolamide
–3.3 ± nr –14.3 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +2 timolol  
+2 brinzolamide
–4.9 ± 2.6 –20.3 ± 10.5
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 25.8 ± 3.0 +2 timolol  
+2 brinzolamide
–8.7 ± 3.9 –33.7 ± 14.7
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 25.9 ± nr +2 timolol  
+2 brinzolamide
–9.1 ± nr –34.9 ± nr
Abbreviations: M, male; F, female;   Y, year; POAG, primary open-angle glaucoma; OHT, ocular hypertension; IOP, intraocular pressure; SD, standard deviation; bid, twice daily; 
tid, thrice daily; nr, not reported.
Acknowledgments and disclosures
Publication support was provided by Alcon Laboratories, 
Inc. The authors have no proprietary interest in the products 
discussed in this manuscript.
References
  1.  European Glaucoma Society. Terminology and guidelines for glaucoma. 
Sivona, Italy: Dogma; 2008.
  2.  Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological 
management of primary open-angle glaucoma: second-line options 
and beyond. Drugs Aging. 2008;25:729–759.
  3.  Cox JA, Mollan SP, Bankart J, Robinson R. Efficacy of antiglaucoma fixed 
combination therapy versus unfixed components in reducing intraocular 
pressure: a systematic review. Br J Ophthalmol. 2008;92:729–734.
  4.  Beckers HJ, Schouten JS, Webers CA, van der Valk R, Hendrikse F. 
Side effects of commonly used glaucoma medications: comparison of 
tolerability, chance of discontinuation, and patient satisfaction. Graefes 
Arch Clin Exp Ophthalmol. 2008;246:1485–1490.
  5.  Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs 
for the treatment of glaucoma. Drugs Aging. 2007;24:1007–1016.
  6  Fechtner RD, Realini T. Fixed combinations of topical glaucoma 
medications. Curr Opin Ophthalmol. 2004;15:132–135.
  7.  Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of 
antiglaucomatous prostaglandin analogues: travoprost with and without 
benzalkonium chloride and preserved latanoprost. Invest Ophthalmol 
Vis Sci. 2007;48:4123–4128.
  8.  Kahook MY, Noecker RJ. Comparison of corneal and conjunctival 
changes after dosing of travoprost preserved with sofZia, latanoprost 
with 0.02% benzalkonium chloride, and preservative-free artificial tears. 
Cornea. 2008;27:339–343.
  9.  Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. 
Ocular symptoms and signs with preserved and preservative-free 
glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
10.  Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms 
and signs with preserved and preservative free glaucoma medication. 
Br J Ophthalmol. 2002;86:418–423.
11  Hommer A, Thygesen J, Ferreras A, et al. A European perspective on 
costs and cost effectiveness of ophthalmic combinations in the treatment 
of open-angle glaucoma. Eur J Ophthalmol. 2008;18:778–786.
12.  Francis BA, Du LT, Berke S, Ehrenhaus M, Minckler DS. Comparing 
the fixed combination dorzolamide-timolol (Cosopt) to concomitant 
administration of 2% dorzolamide (Trusopt) and 0.5% timolol – 
a randomized controlled trial and a replacement study. J Clin Pharm 
Ther. 2004;29:375–380.
13.  Cosopt® [package insert]. Whitehouse Station, NJ: Merck and Co., 
Inc.; 2006.
14.  Trusopt® [package insert]. Whitehouse Station, NJ: Merck and Co., 
Inc.; 2005.
15.  European Agency for the Evaluation of Medical Products. European 
public assessment report and product information on Azarga [online]. 
URL http://www.emea.europa.eu/humandocs/Humans/EPAR/azarga/
azarga.htm. Accessed February 2, 2009.
16.  Azopt® [package insert]. Fort Worth, TX: Alcon Laboratories, 
Inc.; 2008.Clinical Ophthalmology 2009:3 598
Beckers et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
17.  Betimol® [package insert]. Jacksonville, FL: Vistakon Pharmaceuticals, 
LLC; 2006.
18.  Timoptic® [package insert]. Whitehouse Station, NJ: Merck and Co., 
Inc.; 2005.
19.  Istalol® [package insert]. Irvine, CA: Ista Pharmaceuticals, Inc.; 2005.
20.  Iester M. Brinzolamide. Expert Opin Pharmacother. 2008;9:653–662.
21.  Sugrue MF. Pharmacological and ocular hypotensive properties of 
topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000;19: 
87–112.
22.  Holló G. Use of topical carbonic anhydrase inhibition in glaucoma 
treatment. In: Pharmacotherapy in glaucoma. Bern, Switzerland: Hans 
Huber Verlag; 2000.
23.  Liu JH, Medeiros FA, Slight JR, Weinreb RN. Comparing diurnal and 
nocturnal effects of brinzolamide and timolol on intraocular pres-
sure in patients receiving latanoprost monotherapy. Ophthalmology. 
2009;116:449–454.
24.  Konstas AG, Mantziris DA, Maltezos A, Cate EA, Stewart WC. Com-
parison of 24 hour control with Timoptic 0.5% and Timoptic-XE 0.5% 
in exfoliation and primary open-angle glaucoma. Acta Ophthalmol 
Scand. 1999;77:541–543.
25.  Kumar H, Sudan R, Sethi HS, Sony P. Timolol maleate 0.5% versus 
timolol maleate in gel forming solution 0.5% (Timolol GFS) in open 
angle glaucoma in India. Preliminary safety and efficacy study. Indian 
J Ophthalmol. 2002;50:21–23.
26.  Shedden A, Laurence J, Tipping R. Efficacy and tolerability of timolol 
maleate ophthalmic gel-forming solution versus timolol ophthalmic 
solution in adults with open-angle glaucoma or ocular hypertension: a six-
month, double-masked, multicenter study. Clin Ther. 2001;23:440–450.
27.  Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of 
timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or 
ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–2573.
28.  Rojanapongpun P, Drance SM, Morrison BJ. Ophthalmic artery flow 
velocity in glaucomatous and normal subjects. Br J Ophthalmol. 
1993;77:25–29.
29.  Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, 
perfusion pressure, and primary open-angle glaucoma. A population-
based assessment. Arch Ophthalmol. 1995;113:216–221.
30.  Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. 
Large diurnal fluctuations in intraocular pressure are an independent 
risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142.
31.  Bergea B, Bodin L, Svedbergh B. Impact of intraocular pressure 
regulation on visual fields in open-angle glaucoma. Ophthalmology. 
1999;106:997–1004; discussion 1004–1005.
32.  Nouri-Mahdavi K, Hoffman D, Coleman AL, et al. Advanced 
Glaucoma Intervention Study. Predictive factors for glaucomatous 
visual field progression in the Advanced Glaucoma Intervention Study. 
Ophthalmology. 2004;111:1627–1635.
33.  Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intra-
ocular pressure in the aging population. IOVS. 1999;40:2912–2917.
34.  Caprioli J. Intraocular pressure fluctuation: an independent risk factor 
for glaucoma? Arch Ophthalmol. 2007;125:1124–1125.
35.  Carenini AB, Sibour G, Boles Carenini B. Differences in the longterm 
effect of timolol and betaxolol on the pulsatile ocular blood flow. Surv 
Ophthalmol. 1994;38 Suppl:S118–S124.
36.  Lubeck P, Orgul S, Gugleta K, Gherghel D, Gekkieva M, Flammer J. 
Effect of timolol on anterior optic nerve blood flow in patients with 
primary open-angle glaucoma as assessed by the Heidelberg retina 
flowmeter. J Glaucoma. 2001;10:13–17.
37.  Harris A, Spaeth GL, Sergott RC, Katz LJ, Cantor LB, Martin BJ. 
Retrobulbar arterial hemodynamic effects of betaxolol and timolol in 
normal-tension glaucoma. Am J Ophthalmol. 1995;120:168–175.
38.  Yoshida A, Ogasawara H, Fujio N, et al. Comparison of short- and 
long-term effects of betaxolol and timolol on human retinal circulation. 
Eye. 1998;12:848–853.
39.  Liu JH, Li R, Nelson TR, Weinreb RN. Resistance to blood flow in the 
rabbit ophthalmic artery after topical treatment with timolol. J Ocul 
Pharmacol Ther. 2007;23:103–109.
40.  Siesky B, Harris A, Sines D, et al. A comparative analysis of the 
effects of the fixed combination of timolol and dorzolamide versus 
latanoprost plus timolol on ocular hemodynamics and visual function 
in patients with primary open-angle glaucoma. J Ocul Pharmacol Ther. 
2006;22:353–361.
41.  Brogliatti B, Rolle T, Vizzeri GM, Cipullo D. Comparison of the efficacy 
on intraocular pressure and retinal blood flow of a beta-blocker (timolol 
maleate) against the fixed association of a topical carbonic anhydrase 
(dorzolamide) and a beta-blocker (timolol maleate). Acta Ophthalmol 
Scand. 2000;232:47–49.
42.  Rolle T, Tofani F, Brogliatti B, Grignolo FM. The effects of dorzolamide 
2% and dorzolamide/timolol fixed combination on retinal and optic 
nerve head blood flow in primary open-angle glaucoma patients. Eye. 
2008;22:1172–1179.
43.  Martínez A, Sánchez M. A comparison of the effects of 0.005% 
latanoprost and fixed combination dorzolamide/timolol on retrobulbar 
haemodynamics in perviously untreated glaucoma patients. Curr Med 
Res Opin. 2006;22:67–73.
44.  Uva MG, Longo A, Reibaldi M, Reibaldi A. The effect of timolol-
dorzolamide and timolol-pilocarpine combinations on ocular blood flow 
in patients with glaucoma. Am J Ophthalmol. 2006;141:1158–1160.
45.  Janulevicinë I, Harris A, Kagemann L, Siesky B, McCranor L. 
A comparison of theeffects of dorzolamide/timolol fixed combination 
versus latanoprost on intraocular pressure and pulsatile ocular blood 
flow in primary open-angle glaucoma patients. Acta Ophthalmol Scand. 
2004;82:730–737.
46.  Harris A, Jonescu-Cuypers CP, Kagemann L, et al. Effect of dorzol-
amide timolol combination versus timolol 0.5% on ocular bloodflow 
in patients with primary open-angle glaucoma. Am J Ophthalmol. 
2001;132:490–495.
47.  Barnes GE, Li B, Dean T, Chandler ML. Increased optic nerve head 
blood flow after 1week of twice daily topical brinzolamide treatment in 
Dutch-belted rabbits. Surv Ophthalmol. 2000;44(Suppl 2):S131–S140.
48.  Iester M, Altieri M, Michelson G, Vittone P, Traverso CE, Calabria G. 
Retinal peripapillary blood flow before and after topical brinzolamide. 
Ophthalmologica. 2004;218:390–396.
49.  Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects 
of brinzolamide and dorzolamide on retinal oxygen saturation and 
ocular microcirculation in patients with primary open-angle glaucoma. 
Br J Ophthalmol. 2008;92:500–504.
50.  Kaup M, Plange N, Niegel M, Remky A, Arend O. Effects of 
brinzolamide on ocular haemodynamics in healthy volunteers. Br J 
Ophthalmol. 2004;88:257–262.
51.  Klemm M, Zeitz O, Reuss J, Matthiessen ET, Richard G. Therapy 
of normal tension glaucoma: effect of brinzolamide on ocular 
haemodynamics. Klin Monatsbl Augenheilkd. 2003;220:330–333.
52.  van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-
lowering effects of all commonly used glaucoma drugs: a meta-
analysis of randomized clinical trials. Ophthalmology. 2005;112: 
1177–1185.
53.  Webers CA, van der Valk R, Schouten JS, et al. Intraocular pressure-
lowering effect of adding dorzolamide or latanoprost to timolol: 
a meta-analysis of randomized clinical trials. Ophthalmology. 
2007;114:40–46.
54.  Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic 
suspension (Azopt) in patients with open-angle glaucoma or ocular 
hypertension maintained on timolol therapy. Surv Ophthalmol. 
2000;44 Suppl 2:S163–S168.
55.  Michaud JE, Friren B; International Brinzolamide Adjunctive Study 
Group. Comparison of topical brinzolamide 1% and dorzolamide 2% 
eye drops given twice daily in addition to timolol 0.5% in patients with 
primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 
2001;132:235–243.
56.  Martinez A, Sanchez Salorio M. A comparison of the long-term effects 
of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, 
on retrobulbair hemodynamics and intraocular pressure in open-angle 
glaucoma patients. J Ocul Pharmacol Ther. 2009;25:239–248.Clinical Ophthalmology 2009:3
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
599
Brinzolamide/timolol for the treatment of elevated IOP Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
57.  Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering 
efficacy of brinzolamide 1%/timolol 0.5% fixed combination 
compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 
2008;115:1728–1734.
58.  Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 
1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 
0.5% in patients with open-angle glaucoma or ocular hypertension. 
J Glaucoma. 2009;18:293–300.
59.  Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week 
comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic 
suspension fixed combination compared to BID-dosed dorzolamide 2%/
timolol 0.5% ophthalmic solution in patients with open-angle glaucoma 
or ocular hypertension. J Ocul Pharmacol Ther. 2008;24:601–605.
60.  Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension 
compared with dorzolamide 2.0% ophthalmic solution: results from two 
multicenter comfort studies. Brinzolamide Comfort Study Group. Surv 
Ophthalmol. 2000;44(Suppl 2):S141–S145.
61.  Tsukamoto H, Noma H, Mukai S, Ikeda H, Mishima HK. The efficacy 
and ocular discomfort of substituting brinzolamide for dorzolamide in 
combination therapy with latanoprost, timolol, and dorzolamide. J Ocul 
Pharmacol Ther. 2005;21:395–399.
62.  Barnebey H, Kwok SY. Patients’ acceptance of a switch from 
dorzolamide to brinzolamide for the treatment of glaucoma in a clinical 
practice setting. Clin Ther. 2000;22:1204–1212.
63.  Mundorf T, Rauchman S, Williams R, Notivol R. A patient preference 
comparison of Azarga™ (brinzolamide/timolol fixed combination) vs 
Cosopt® (dorzolamide/timolol fixed combination) in patients with 
open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 
2008;2:623–628.
64.  Jampel HD, Schwartz GF, Robin AL, Abrams DA, Johnson E, Miller RB. 
Patient preferences for eye drop characteristics: a willingness-to-pay 
analysis. Arch Ophthalmol. 2003;121:540–546.